Bio-Rad Laboratories(BIO-B)

Focus: Bio-Rad Laboratories is a public diagnostic and life sciences company with $2.7B in annual revenue, operating across clinical diagnostics, blood banking, and laboratory instrumentation markets. With 5,001–10,000 employees, the company serves global healthcare systems and research institutions.

Profile data last refreshed 12h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

5001-10000

Open Jobs

About Bio-Rad Laboratories

AI assessmentNot Hiring

No open roles listed right now. Follow Bio-Rad Laboratories to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$2.7B

Key Products

Bio-Rad Platelia Dengue NS1 Ag test

Mass Screening / Dengue

Growth

Rapid point-of-care diagnostic for dengue screening in endemic regions; supports public health initiatives.

Geenius HIV1/2 Supplemental Assay

HIV Diagnosis

Help build intelligence for Bio-Rad Laboratories

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established $2.7B public company with multi-decade track record in diagnostics and life sciences instrumentation
Diversified portfolio across clinical diagnostics (HIV, dengue, sepsis) reduces single-product dependency risk
Global scale (5,000+ employees) offers career mobility and cross-functional exposure in regulated diagnostic workflows

Watch Out For

Company reported significant net losses ($637M in FY2025, $3.6B in FY2024), signaling financial distress or major restructuring
Pipeline is diagnostics-focused with minimal late-stage drug development (0 Phase 2/3 programs); limited traditional pharma career trajectory
Currently zero active job openings reported, suggesting a hiring freeze or capacity reduction

Generated by Claude from Bio-Rad Laboratories's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Confirmatory assay in HIV diagnostic algorithms; addresses ongoing global testing demand.

Pipeline & Clinical Trials

additional blood tubes

Sepsis

N/A

Geenius HIV1/2 Supplemental Assay

HIV

N/A

Bio-Rad Platelia Dengue NS1 Ag test

Mass Screening

N/A

blood sampling

Sepsis

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$2.7B5%

R&D Spend

$247M(9%)4%

Net Income

-$637M

Cash

$404M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

WARN Act Layoff Notices (1)

2025-02-10

1 employees affected— 2500 Atlas Avenue Richmond CA 94806, CA

source

Source: state DOL filings, aggregated via Big Local News

No reported FDA warnings or WARN Act filings provide some operational stability, but the scale of net losses and hiring freeze warrant due diligence during interviews.